Results 41 to 50 of about 60,520 (273)

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 2; peer review: 2 approved]

F1000Research, 2023
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden-A Register-Based Study. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Purpose This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes. Methods Children aged 5–17 years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers.
Kimland EE, Sundström A, Wikström S, Jarbin H, Dahlén E.   +4 more
europepmc   +2 more sources

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

New England Journal of Medicine, 2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy. METHODS In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination ...
R. Navari, R. Qin, K. Ruddy, Heshan Liu, S. Powell, Madhuri Bajaj, L. Dietrich, D. Biggs, J. Lafky, C. Loprinzi   +9 more
semanticscholar   +1 more source

Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020
AIMS The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats. METHODS Rats were randomly divided into three groups: the control (Control) group, the olanzapine (Ola) group and the ...
Cui-Lian Guo, Jin-xin Liu, Huqun Li
semanticscholar   +1 more source

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine [PDF]

, 2002
The aim of this investigation was to compare the degree of striatal dopamine-(D2) receptor blockade by two atypical antipsychotic drugs, risperidone and olanzapine.
Tatsch, K., Frodl, T., Preuss, Ulrich W., Rossmüller, B., Möller, H.-J., Preuss, U. W., Meisenzahl, E. M., Schmitt, G. J. E., Dresel, S., Hahn, K.   +9 more
core   +1 more source

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Neuropsychiatric Disease and Treatment, 2021
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894.
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D   +9 more
doaj  

Macrophage-derived secretome is sufficient to confer olanzapine-mediated insulin resistance in human adipocytes

Comprehensive Psychoneuroendocrinology, 2021
Objective: Olanzapine and Aripiprazole are widely used second-generation antipsychotic drugs. Olanzapine, more than Aripiprazole, leads to considerable metabolic side effects including obesity and diabetes.
Priya Dipta, Assel Sarsenbayeva, Miriam Shmuel, Francesca Forno, Jan W. Eriksson, Maria J. Pereira, Xesús M. Abalo, Martin Wabitsch, Morten Thaysen-Andersen, Boaz Tirosh   +9 more
doaj   +1 more source

Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane

Journal of Nutritional Biochemistry, 2020
Olanzapine is effective to treat for schizophrenia and other mood disorders, but limited by side effects such as weight gain, dyslipidemia, and liver injury. Obesity in the US is at epidemic levels, and is a significant risk factor for drug-induced liver
Robin H. Isaacson, J. Beier, N. Khoo, B. Freeman, Z. Freyberg, G. Arteel   +5 more
semanticscholar   +1 more source

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.

American Journal of Psychiatry, 2019
OBJECTIVE Preclinical evidence and data from a proof-of-concept study in healthy volunteers suggest that samidorphan, an opioid antagonist, mitigates weight gain associated with olanzapine.
William F. Martin, C. Correll, P. Weiden, Ying Jiang, S. Pathak, Lauren DiPetrillo, B. Silverman, E. Ehrich   +7 more
semanticscholar   +1 more source